Natalizumab adverse events are rare in patients with multiple sclerosis

被引：13

作者：

Fragoso, Yara Dadalti ^{[1
]}

Alves-Leon, Soniza Vieira ^{[2
]}

Arruda, Walter Oleschko ^{[3
]}

Carvalho, Margarete de Jesus ^{[4
]}

Comini-Frota, Elizabeth Regina ^{[5
]}

Correa, Eber Castro ^{[6
]}

Brito Ferreira, Maria Lucia ^{[7
]}

da Gama, Paulo Diniz ^{[8
]}

Gomes, Sidney ^{[9
,10
]}

Magno Goncalves, Marcus Vinicius ^{[11
]}

Kaimen-Maciel, Damacio Ramon ^{[12
]}

Mendes, Maria Fernando ^{[13
]}

Morales, Rogerio Rizo ^{[14
]}

Muniz, Andre ^{[15
]}

Salgado, Pedro Rippel ^{[16
]}

Ruocco, Heloisa Helena ^{[17
]}

Bezerra de Albuquerque, Livia Brito ^{[7
]}

Bidin Brooks, Joseph Bruno ^{[1
]}

Fezer, Leticia ^{[2
]}

Georgetto, Sergio ^{[12
]}

Lopes, Josiane ^{[12
]}

Malfetano, Fabiola Rachid ^{[2
]}

Meira, Isabella D'Andrea ^{[2
]}

Silva Oliveira, Celso Luis ^{[1
]}

Meneses de Oliveira, Francisco Tomaz ^{[9
,10
]}

Safanelli, Fabiana ^{[11
]}

Satomi, Massaco ^{[16
]}

机构：

[1] Univ Metropolitana Santos UNIMES, Santos, SP, Brazil

[2] Univ Fed Rio de Janeiro UFRJ, Rio De Janeiro, RJ, Brazil

[3] Univ Fed Parana UFPR, Curitiba, PR, Brazil

[4] Fac Med ABC FMABC, Santo Andre, SP, Brazil

[5] Univ Fed Minas Gerais UFMG, Belo Horizonte, MG, Brazil

[6] CLINEN, Brasilia, DF, Brazil

[7] Hosp Restauracao, Recife, PE, Brazil

[8] Pontificia Univ Catolica Sao Paulo PUC SP, Sorocaba, SP, Brazil

[9] Hosp Beneficencia Portuguesa Sao Paulo, Sao Paulo, Brazil

[10] Hosp Paulistano, Sao Paulo, Brazil

[11] Univ Regiao Joinville UNIVILLE, Joinville, SC, Brazil

[12] Univ Estadual Londrina UEL, Londrina, PR, Brazil

[13] Fac Ciencias Med Santa Casa Sao Paulo FCMSCSP, Sao Paulo, Brazil

[14] Univ Fed Uberlandia UFU, Uberlandia, MG, Brazil

[15] Hosp Sao Rafael Salvador, Salvador, BA, Brazil

[16] Univ Fed Mato Grosso Sul UFMS, Campo Grande, MS, Brazil

[17] Ctr Atendimento Esclerose Multipla, Jundiai, SP, Brazil

来源：

ARQUIVOS DE NEURO-PSIQUIATRIA | 2013年 / 71卷 / 03期

关键词：

multiple sclerosis; natalizumab; adverse events; antibodies; monoclonal; INFUSION REACTIONS;

D O I：

10.1590/S0004-282X2013000300002

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Objective: To assess the prevalence and the profile of adverse events (AE) of natalizumab in patients with multiple sclerosis (MS). Methods: Data collection from neurologists attending to patients with MS at specialized units in Brazil. Results: Data from 103 patients attending the infusion centers of 16 MS units in 9 Brazilian states were included in the study. The total number of infusions was 1,042. Seventy-nine patients (76.7%) did not present any AE. Twenty-four patients (23.3%) presented only mild AE. There were three major AE, including two deaths. These three occurrences, although not necessarily being drug-related, must be taken into consideration. Conclusion: The profile of AEs for natalizumab shows that 97% of patients have none or only mild AE. However, still due to safety worries, the use of this medication should be restricted to MS units under the care of specialized neurologists.

引用

页码：137 / 141

页数：5

共 50 条

[41] Efficacy of Natalizumab in African American Multiple Sclerosis Patients
Perumal, Jai S.
Laing, Lisa S.
Gazivoda, Kristina S.
Babinski, Kristen
Howard, Jonathan
Kister, Ilya
Herbert, Joseph
NEUROLOGY, 2011, 76 (09) : A474 - A474
[42] Immune surveillance in multiple sclerosis patients treated with natalizumab
Stuve, O
Marra, C
Jerome, KR
Cook, L
Cravens, PD
Cepok, S
Frohman, E
Phillips, T
Arendt, G
Hemmer, B
Monson, N
Racke, MK
NEUROLOGY, 2006, 66 (05) : A250 - A250
[43] Anti-Natalizumab Antibodies in Patients with Multiple Sclerosis
Lundkvist, Malin
Engdahl, Elin
Holmen, Carolina
Moverare, Robert
Olsson, Tomas
Hillert, Jan
Fogdell-Hahn, Anna
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2012, 76 (02) : 206 - 207
[44] Glioblastoma in natalizumab-treated multiple sclerosis patients
Morales, Fabian Sierra
Wright, Robert B.
Novo, Jorge E.
Arvanitis, Leonidas D.
Stefoski, Dusan
Koralnik, Igor J.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2017, 4 (07): : 512 - 516
[45] Uncommon infections in multiple sclerosis patients treated with natalizumab
Fritz-Fiaux, A.
Goebels, N.
MULTIPLE SCLEROSIS, 2009, 15 (09): : S124 - S124
[46] Natalizumab: Risk Stratification of Individual Patients with Multiple Sclerosis
Tur, Carmen
Montalban, Xavier
CNS DRUGS, 2014, 28 (07) : 641 - 648
[47] Management of cutaneous adverse events associated with daclizumab treatment in multiple sclerosis patients
Shen, J.
Harris, V.
Parratt, J.
Smith, S.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 82 - 83
[48] Natalizumab in multiple sclerosis patients with high active disease
Cobo, A.
Bau, L.
Matas, E.
Mane, M. A.
Martinez-Yelamos, A.
Romero-Pinel, L.
Martinez-Yelamos, S.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 455 - 455
[49] Efficacy of Natalizumab in a French Cohort of Multiple Sclerosis Patients
Outteryck, Olivier
Ongagna, Jean-Claude
Zephir, Helene
Fleury, M. -C.
Lacour, Arnaud
Blanc, Frederic
Vermersch, Patrick
de Seze, Jerome
NEUROLOGY, 2010, 74 (09) : A550 - A551
[50] Natalizumab Treatment in Multiple Sclerosis
Kurtuncu, Murat
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2011, 48 : 56 - 60

← 1 2 3 4 5 →